Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOR/ISL vs Biktarvy in treatment-naïve HIV-1 infection
2022-502099-22-00Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing DOR/ISL arm with Biktarvy arm (2 arms). Primary endpoints: Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48, Percentage of participants experiencing ≥1 adverse event (AE) through Week 48 and 1 more. Planned start Apr 2023; status: withdrawn.
02
Drugs
doravirine + islatravirbictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2022-502099-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502099-22-00.